We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.

Close

Vaccine Evaluation Unit

Public Health England's Vaccine Evaluation Unit (VEU) specialises in serological determination of immune responses to Neisseria meningitidis and Streptococcus pneumoniae either following vaccination or disease. It has international recognition for all of the assays that encompass serum bactericidal antibody assays and ELISA for all serogroups of N. meningitidis as well as offering determination of IgG concentrations for pneumococcal (serotype-specific), Haemophilus influenzae type b, tetanus and diphtheria.

The VEU underpinned the implementation of the meningococcal serogroup C conjugate vaccine in the UK with performance of meningococcal serological assays and redefining the correlates of protection. Currently, the VEU is involved in a similar project that has led to the implementation of a serogroup A vaccine in Sub-Saharan Africa. The VEU is currently collaborating on studies with the Saudi Arabian Ministry of Health to inform on future immunisation policies. It offers a range of validated assays for meningococcal serogroup B and is involved in many vaccine trials both here and overseas.

The pneumococcal serology assays are now widely used by clinicians as well as for vaccine trials and were incorporated into the vaccine surveillance of the impact of the pneumococcal conjugate vaccination programme for children in England, Wales and Northern Ireland.

The VEU also now houses the Seroepidemiology Unit (SEU). VEU has been involved in serosurveys for pneumococcal antibodies, meningococcal serogroups A, C, Y and W as well as serogroup B serology and human papilloma IgG. VEU also evaluate new kits for the SEU. The total workload is approximately 200,000 assays per annum.

Research

The VEU has an active research programme and encourages collaborations locally, nationally and internationally.

Ongoing projects include novel platforms for multiplexing assays, immunoassays for Human Papilloma Virus.

Nationally, the VEU is a key player in the National Vaccine Evaluation Consortium and UK Paediatric Vaccine Group whilst internationally advises WHO on serological assays for meningococci together with strong links to most vaccine manufacturers who use the Unit as a reference centre.

The VEU is also committed to training of staff from laboratories both nationally and internationally, particularly those from developing countries.

Quality

The VEU is committed to providing a quality service which meets the requirements, expectations and demands of the client.

Clinical trial clients will be provided with a service in compliance with:

  • the principles of Good Clinical Practice, as detailed in EU Directive 2001/20/EC [NB: the Clinical Trials Regulation (Regulation (EU) No 536/2014) which repeals Directive 2001/20EC will come into effect on 28 May 2016]
  • the Medicine and Healthcare products Regulatory Agency (MHRA) guidance on the maintenance of regulatory compliance in laboratories that perform the analysis or evaluation of clinical trial samples.

Laboratory opening hours

The VEU is open: Monday to Friday: 8.00am - 5.00pm

Clinical advice

Results: For general results/enquiries: Tel: 0161 276 8854 or 0161 276 8788

Out-of-Hours Service: There is no out-of-hours service for the Vaccine Evaluation Unit.

For further information about the Sera-epidemiology Unit (SEU) please contact ezra.linley@phe.gov.uk.

For general information see Public Health England

Contact details

Name External numbers Internal numbers
Prof Ray Borrow
Head of VEU/Consultant Clinical Scientist
(0161) 276 8850 68850
Dr Jamie Findlow
Deputy Head of VEU/ Clinical Scientist
(0161) 701 5303 15303

Dr Emma Newton, Clinical Serology
Clinical Scientist

(0161) 276 6791 66791

Dr Ezra Linley,  SEU
Pre-Registered Clinical Scientist

(0161) 276 8842 68842

Mrs Debbie Cummings
PA/Unit Administrator

(0161) 276 6793 66793

Mrs Nilofer Razzaq
PA/Unit Administrator (Mon, Tues)

(0161) 276 5697 65697

Mrs Nicola Boothman
PA/Unit Administrator (Wed, Thurs, Fri)

(0161) 276 5697 65697

VEU Fax No:

(0161) 276 5744 NA

Postal address:

Public Health England
Public Health Laboratory - Manchester
Vaccine Evaluation Unit
Manchester Medical Microbiology Partnership
2nd Floor, Clinical Sciences Building II
Manchester Royal Infirmary, Oxford Road
MANCHESTER
M13 9WL
UK

Delivery address:

Public Health England
Public Health Laboratory - Manchester
Vaccine Evaluation Unit
Manchester Medical Microbiology Partnership
PO Box 209, 2nd Floor, Clinical Sciences Building II
Manchester Royal Infirmary, Oxford Road
MANCHESTER
M13 9WZ
UK

DX address:

Manchester Medical Microbiology Partnership
DX69624410
Manchester 90 M

Public Health England's Vaccine Evaluation Unit (VEU) specialises in serological determination of immune responses to Neisseria meningitidis and Streptococcus pneumoniae either following vaccination or disease. It has international recognition for all of the assays that encompass serum bactericidal antibody assays and ELISA for all serogroups of N. meningitidis as well as offering determination of IgG concentrations for pneumococcal (serotype-specific), Haemophilus influenzae type b, tetanus and diphtheria.

The VEU underpinned the implementation of the meningococcal serogroup C conjugate vaccine in the UK with performance of meningococcal serological assays and redefining the correlates of protection. Currently, the VEU is involved in a similar project that has led to the implementation of a serogroup A vaccine in Sub-Saharan Africa. The VEU is currently collaborating on studies with the Saudi Arabian Ministry of Health to inform on future immunisation policies. It offers a range of validated assays for meningococcal serogroup B and is involved in many vaccine trials both here and overseas.

The pneumococcal serology assays are now widely used by clinicians as well as for vaccine trials and were incorporated into the vaccine surveillance of the impact of the pneumococcal conjugate vaccination programme for children in England, Wales and Northern Ireland.

The VEU also now houses the Seroepidemiology Unit (SEU). VEU has been involved in serosurveys for pneumococcal antibodies, meningococcal serogroups A, C, Y and W as well as serogroup B serology and human papilloma IgG. VEU also evaluate new kits for the SEU. The total workload is approximately 200,000 assays per annum.

Research

The VEU has an active research programme and encourages collaborations locally, nationally and internationally.

Ongoing projects include novel platforms for multiplexing assays, immunoassays for Human Papilloma Virus.

Nationally, the VEU is a key player in the National Vaccine Evaluation Consortium and UK Paediatric Vaccine Group whilst internationally advises WHO on serological assays for meningococci together with strong links to most vaccine manufacturers who use the Unit as a reference centre.

The VEU is also committed to training of staff from laboratories both nationally and internationally, particularly those from developing countries.

Quality

The VEU is committed to providing a quality service which meets the requirements, expectations and demands of the client.

Clinical trial clients will be provided with a service in compliance with;:

· the principles of Good Clinical Practice, as detailed in EU Directive 2001/20/EC [NB: the Clinical Trials Regulation ( Regulation (EU) No 536/2014  ) which repeals Directive  2001/20EC will come into effect on 28 May 2016]

· the Medicine and Healthcare products Regulatory Agency (MHRA) guidance on the maintenance of regulatory compliance in laboratories that perform the analysis or evaluation of clinical trial samples.

Laboratory opening hours

 

The VEU is open: Monday to Friday: 8.00am -5.00pm

Clinical Advice

 

Results : For general results/enquiries: Tel: 0161 276 8854 or 0161 276 8788

Out-of-Hours Service: There is no out-of-hours service for the Vaccine Evaluation Unit.

For further information about the Sera-epidemiology Unit (SEU) please contact ezra.linley@phe.gov.uk.

For general information, please visit the website below. https://www.gov.uk/government/organisations/public-health-england

Public Health England's Vaccine Evaluation Unit (VEU) specialises in serological determination of immune responses to Neisseria meningitidis and Streptococcus pneumoniae either following vaccination or disease. It has international recognition for all of the assays that encompass serum bactericidal antibody assays and ELISA for all serogroups of N. meningitidis as well as offering determination of IgG concentrations for pneumococcal (serotype-specific), Haemophilus influenzae type b, tetanus and diphtheria.

The VEU underpinned the implementation of the meningococcal serogroup C conjugate vaccine in the UK with performance of meningococcal serological assays and redefining the correlates of protection. Currently, the VEU is involved in a similar project that has led to the implementation of a serogroup A vaccine in Sub-Saharan Africa. The VEU is currently collaborating on studies with the Saudi Arabian Ministry of Health to inform on future immunisation policies. It offers a range of validated assays for meningococcal serogroup B and is involved in many vaccine trials both here and overseas.

The pneumococcal serology assays are now widely used by clinicians as well as for vaccine trials and were incorporated into the vaccine surveillance of the impact of the pneumococcal conjugate vaccination programme for children in England, Wales and Northern Ireland.

The VEU also now houses the Seroepidemiology Unit (SEU). VEU has been involved in serosurveys for pneumococcal antibodies, meningococcal serogroups A, C, Y and W as well as serogroup B serology and human papilloma IgG. VEU also evaluate new kits for the SEU. The total workload is approximately 200,000 assays per annum.

Research

The VEU has an active research programme and encourages collaborations locally, nationally and internationally.

Ongoing projects include novel platforms for multiplexing assays, immunoassays for Human Papilloma Virus.

Nationally, the VEU is a key player in the National Vaccine Evaluation Consortium and UK Paediatric Vaccine Group whilst internationally advises WHO on serological assays for meningococci together with strong links to most vaccine manufacturers who use the Unit as a reference centre.

The VEU is also committed to training of staff from laboratories both nationally and internationally, particularly those from developing countries.

Quality

The VEU is committed to providing a quality service which meets the requirements, expectations and demands of the client.

Clinical trial clients will be provided with a service in compliance with;:

 

  • the principles of Good Clinical Practice, as detailed in EU Directive 2001/20/EC [NB: the Clinical Trials Regulation ( Regulation (EU) No 536/2014  ) which repeals Directive  2001/20EC will come into effect on 28 May 2016]

 

  • the Medicine and Healthcare products Regulatory Agency (MHRA) guidance on the maintenance of regulatory compliance in laboratories that perform the analysis or evaluation of clinical trial samples.

 

Laboratory opening hours

 

The VEU is open:    Monday to Friday: 8.00am -5.00pm

 

Clinical Advice

 

Results:   For general results/enquiries: Tel: 0161 276 8854 or 0161 276 8788

Out-of-Hours Service:  There is no out-of-hours service for the Vaccine Evaluation Unit.

For further information about the Sera-epidemiology Unit (SEU) please contact ezra.linley@phe.gov.uk.

For general information, please visit the website below.   https://www.gov.uk/government/organisations/public-health-england